Devices and Diagnostics

Lahav Gil and Nir Katchinskiy, PhD - Pulse Medica

A Laser-Focused Business Model, With Nir Katchinskiy and Lahav Gil

By Priscilla Villarreal | February 2, 2022

  PODCAST EPISODE 315 Click here to watch the video version of this podcast. Retina specialists have limited imaging and surgical tools to visualize the…

Read More

Faster, Better, Smarter, Cheaper With MacuLogix’s Bill McPhee

By Rich Kirkner | November 17, 2021

Even the most groundbreaking device won’t go far if doctors can’t easily adopt it into their practice. PODCAST EPISODE 306

Read More

Solving the Dry Eye Mystery With Neurolens’ Jeffrey Krall, OD

By Jackie Wengrod | October 4, 2021


Read More

Revolutionizing Cataract Surgery from Innovation to Commercialization

By Jackie Wengrod | September 22, 2021


Read More
OIS Summit FDA Approved (2)

Judy Gordon’s Legacy: Helping Firms Navigate a Path to FDA Approval of Transformative Technology

By Keith Croes | September 7, 2021

Judy Gordon, DVM, is not a job-hopper. When Laguna Beach, Calif.-based ClinReg Consulting Services, a company she founded in 1998, announced her retirement in March,…

Read More
Bausch + Lomb

OSD Pipeline Update: Etiology-Specific Treatments for MGD, Demodex Getting Closer

By Conni Bergmann Koury | August 31, 2021

First-in-class drugs are being investigated to treat two etiologies of dry eye disease (DED)—meibomian gland dysfunction (MGD) and Demodex blepharitis—both highly prevalent conditions for which…

Read More

Drug Developers Show Renewed Interest in Ocular Allergies

By Karen Blum | August 24, 2021

The ocular allergy space has seen some renewed interest lately, with Food and Drug Administration approval of Santen Pharmaceutical’s new drug for vernal keratoconjunctivitis (VKC)…

Read More
Pierre Billardon

Leading a Global Leader, with Pierre Billardon

By Jackie Wengrod | August 24, 2021


Read More
FDA rejected Abicipar

A Year After FDA Rejected Abicipar, AbbVie Gives It Back to Molecular Partners

By Rich Kirkner | August 17, 2021

In the summer of 2020, shortly after the US Food and Drug Administration issued a negative Complete Response Letter to AbbVie and Molecular Partners, rejecting…

Read More

Second Sight Gets a Double-Shot Boost Thanks to PO and NIH installment

By Rich Kirkner | July 13, 2021

Up until a few weeks ago, 2021 had been an up-and-down year for retinal prosthesis maker Second Sight Medical Products, but it recently got a…

Read More
OIS Myopia Innovation Showcase Panel

The Myopia Management Market: ‘How Big is Big?’

By Steve Lenier | May 4, 2021

“How big is big?” That was a question that Dwight Akerman, OD, MBA, FAAO, FBCLA, put to a panel of industry insiders at last week’s…

Read More
Emerging Glaucoma Devices See Beyond IOP

Emerging Glaucoma Devices See Beyond IOP

By Heather Johnson | May 27, 2020

The glaucoma space has been dominated by a host of products designed to lower intraocular pressure (IOP) – minimally invasive glaucoma surgery (MIGS) devices and…

Read More


Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.